DOC Stock Analysis: Healthpeak Properties | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 13.867m USD | 12M Return: 23.3% | US42250P1030 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 116M
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Healthpeak Properties, Inc. (NYSE: DOC) is a large-cap real estate investment trust (REIT) and S&P 500 constituent that owns, operates, and develops real estate focused on healthcare discovery and delivery. The company is headquartered in Denver, Colorado, was incorporated in Maryland in 1985, and has been publicly traded since 1987.
As a REIT, Healthpeak is generally required to distribute the majority of its taxable income to shareholders as dividends in exchange for pass-through tax treatment. Within the GICS classification system, the company sits in the Health Care REITs sub-industry, a sector that invests in property types such as medical office buildings, outpatient facilities, senior housing, and life science and research campuses.
- Medical outpatient and lab occupancy drives same-store NOI growth
- Interest rate volatility pressures cap rates and borrowing costs
- Capital recycling funds acquisitions of higher-yielding outpatient medical assets
| Net Income: 407.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.61 > 1.0 |
| NWC/Revenue: 3.12% < 20% (prev -5.18%; Δ 8.30% < -1%) |
| CFO/TA 0.06 > 3% & CFO 1.25b > Net Income 407.5m |
| Net Debt (10.3b) to EBITDA (1.76b): 5.82 < 3 |
| Current Ratio: 1.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (950.4m) vs 12m ago 36.48% < -2% |
| Gross Margin: 22.48% > 18% (prev 60.08%; Δ -37.60% > 0.5%) |
| Asset Turnover: 13.44% > 50% (prev 14.30%; Δ -0.86% > 0%) |
| Interest Coverage Ratio: 1.93 > 6 (EBIT TTM 665.1m / Interest Expense TTM 344.1m) |
| A: 0.00 (Total Current Assets 1.07b - Total Current Liabilities 985.3m) / Total Assets 22.4b |
| B: -0.27 (Retained Earnings -5.95b / Total Assets 22.4b) |
| C: 0.03 (EBIT TTM 665.1m / Avg Total Assets 21.0b) |
| D: 0.62 (Book Value of Equity 7.50b / Total Liabilities 12.0b) |
| Altman-Z'' = 0.03 = B |
As of November 09, 2026, the stock is trading at USD 20.26 with a total of 5,994,739 shares traded. Over the past week, the price has changed by +6.46%, over one month by +7.21%, over three months by -2.50% and over the past year by +23.27%.
Current recommended Stop Loss: 19.50 (which is 3.8% or 1.5 ATR below the current price).
Healthpeak Properties has received a consensus analysts rating of 3.64. Therefore, it is recommended to hold DOC.
- StrongBuy: 6
- Buy: 2
- Hold: 14
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 22.4 | 10.5% |
P/E Trailing = 36.2222
P/E Forward = 161.2903
P/S = 4.701
P/B = 1.7122
P/EG = 4.0809
Revenue TTM = 2.82b USD
EBIT TTM = 665.1m USD
EBITDA TTM = 1.76b USD
Long Term Debt = 8.77b USD (from longTermDebt, last fiscal year)
Short Term Debt = 995.0m USD (from shortTermDebt, last fiscal year)
Debt = 10.7b USD (from shortLongTermDebtTotal, last fiscal year) + Leases 288.2m
Net Debt = 10.3b USD (calculated: Debt 10.7b - CCE 467.5m)
Enterprise Value = 24.1b USD (13.9b + Debt 10.7b - CCE 467.5m)
Interest Coverage Ratio = 1.93 (Ebit TTM 665.1m / Interest Expense TTM 344.1m)
EV/FCF = 19.27x (Enterprise Value 24.1b / FCF TTM 1.25b)
FCF Yield = 5.19% (FCF TTM 1.25b / Enterprise Value 24.1b)
FCF Margin = 44.36% (FCF TTM 1.25b / Revenue TTM 2.82b)
Net Margin = 14.44% (Net Income TTM 407.5m / Revenue TTM 2.82b)
Gross Margin = 22.48% ((Revenue TTM 2.82b - Cost of Revenue TTM 2.19b) / Revenue TTM)
Gross Margin QoQ = none% (prev 56.83%)
Tobins Q-Ratio = 1.08 (Enterprise Value 24.1b / Total Assets 22.4b)
Interest Expense / Debt = 3.21% (Interest Expense 344.1m / Debt 10.7b)
Taxrate = 1.44% (6.17m / 427.5m)
NOPAT = 655.5m (EBIT 665.1m * (1 - 1.44%))
Current Ratio = 1.09 (Total Current Assets 1.07b / Total Current Liabilities 985.3m)
Debt / Equity = 1.43 (Debt 10.7b / totalStockholderEquity, last fiscal year 7.50b)
Debt / EBITDA = 5.82 (Net Debt 10.3b / EBITDA 1.76b)
Debt / FCF = 8.20 (Net Debt 10.3b / FCF TTM 1.25b)
Total Stockholder Equity = 7.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.94% (Net Income 407.5m / Total Assets 22.4b)
RoE = 5.30% (Net Income TTM 407.5m / Total Stockholder Equity 7.69b)
RoCE = 4.04% (EBIT 665.1m / Capital Employed (Equity 7.69b + L.T.Debt 8.77b))
RoIC = 2.94% (NOPAT 655.5m / Invested Capital 22.3b)
WACC = 4.81% (E(13.9b)/V(24.6b) * Re(6.08%) + D(10.7b)/V(24.6b) * Rd(3.21%) * (1-Tc(0.01)))
Discount Rate = 6.08% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 48.58 | Cagr: 14.32%
[DCF] Terminal Value 75.84% ; FCFF base≈1.24b ; Y1≈1.27b ; Y5≈1.42b
[DCF] Fair Price = 16.99 (EV 22.0b - Net Debt 10.3b = Equity 11.7b / Shares 689.5m; r=8.35% [WACC [floored]]; 5y FCF grow 3.11% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.08 | # QB: 0
Revenue Correlation: 94.83 | Revenue CAGR: 12.70% | SUE: N/A | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.03 | Chg30d=N/A | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=0.09 | Chg30d=+0.00% | Revisions=-25% | GrowthEPS=+130.8% | GrowthRev=+6.1%
EPS next Year (2027-12-31): EPS=0.14 | Chg30d=+0.00% | Revisions=-25% | GrowthEPS=+55.6% | GrowthRev=+8.2%
[Analyst] Revisions Ratio: -40% (up=0, down=2)